NSABP B-30: Amenorrhea relates to survival

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

In a subset of 2,366 patients from NSABP B-30 with menstrual history available at follow-up, amenorrheic patients (≥ six months) had significantly improved overall and diseasefree survival across treatment arms. Mortality was significantly reduced by 24% and recurrence by 30%.

In a subset of 2,366 patients from NSABP B-30 with menstrual history available at follow-up, amenorrheic patients (≥ six months) had significantly improved overall and diseasefree survival across treatment arms. Mortality was significantly reduced by 24% and recurrence by 30%.

Of 2,111 patients with follow-up quality-of-life data, QOL (by FACT-B rating scale) and symptoms were essentially the same for all regimens at all time points. The exception was the six-month assessment, where patients receiving AC→T had significantly lower QOL and higher symptom scores, but both measurements later returned to baseline (abstract 75). Younger women had more severe symptoms independent of the development of amenorrhea. Persistent amenorrhea was least severe in the AT arm, reported Patricia Ganz, MD, of the University of California, Los Angeles.

“This information about quality of life, symptoms, and amenorrhea risk can be useful in making treatment decisions,” Dr. Ganz said, suggesting AT as an alternative for women in whom preservation of fertility is paramount over the modest improvement in survival.

Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
A panel of 4 experts on multiple myeloma
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content